摘要
目的研究Ⅱ+Ⅲ期直肠癌根治术后卡培他滨单药或联合奥沙利铂同期放化疗的效果。方法将直肠癌患者180例随机分为A、B组,每组各90例。A组为Ⅱ+Ⅲ期直肠癌根治术后卡培他滨单药同期放化疗,B组为Ⅱ+Ⅲ期直肠癌根治术后卡培他滨联合奥沙利铂同期放化疗。观察2组的治疗效果和不良反应情况。结果相对A组,B组患者在治疗总有效率、中位生存期以及总生存率方面略有优势,但差异不具有统计学意义,P>0.05。在同期放化疗不良反应Ⅰ~Ⅳ级内,相对A组,B组患者在恶心、呕吐、腹泻、血小板减少、手足综合征以及神经系统毒性等方面表现明显较差,差异具有统计学意义,P<0.05。在同期放化疗不良反应Ⅲ~Ⅳ级内,相对A组,B组患者在腹泻方面表现明显较差,差异具有统计学意义,P<0.05。结论Ⅱ+Ⅲ期直肠癌根治术后卡培他滨单药与卡培他滨联合奥沙利铂进行同期放化疗均取得了较好的治疗效果,虽然卡培他滨联合奥沙利铂进行同期放化疗效果略优于卡培他滨单药,但是,其不良反应也较为明显。
Objective To study the curative effects of capecitabine or capecitabine combined with oxaliplatin for Ⅱ + Ⅲrectal cancer after radical resection. Methods 180 patients with rectal cancer were randomly divided into 2 groups,90 cases in each. The group A received capecitabine chemoradiotherapy after radical resection of Ⅱ + Ⅲ rectal carcinoma,the group B received capecitabine combined with oxaliplatin chemoradiotherapy after radical resection of Ⅱ + Ⅲ rectal cancer,efficacy and adverse reactions of the 2 groups were observed. Results Compared with group A,the group B had advantage in total effective rate,median survival and overall survival,the difference was not statistically significant,P > 0. 05. In the Ⅰ ~ Ⅳ adverse reactions of chemoradiotherapy,compared with group A,nausea,vomiting,diarrhea,hand foot syndrome,thrombocytopenia and nervous system toxicity and other aspects of the performance of group B were poor,the difference was statistically significant,P < 0. 05. In the Ⅲ~ Ⅳ adverse reactions of concurrent chemoradiotherapy,compared with group A,the group B was significantly worse in diarrhea,the difference was statistically significant,P < 0. 05. Conclusion Capecitabine or capecitabine combined with oxaliplatin for Ⅱ+ Ⅲ rectal cancer after radical resection is effective,although capecitabine plus oxaliplatin has slightly better effects than that of capecitabine monotherapy,the adverse reactions is also more obvious.
出处
《实用癌症杂志》
2015年第5期714-716,共3页
The Practical Journal of Cancer
关键词
Ⅱ+Ⅲ期直肠癌
根治术后
卡培他滨
奥沙利铂
放化疗
Ⅱ + Ⅲ rectal cancer
Radical resection
Capecitabine
Oxaliplatin
Chemoradiotherapy
